Filing summary
Entity and period: The supplied filing is for Ecology Coatings, Inc., not ABVC Biopharma, Inc. It reports the quarter and six months ended March 31, 2013, with comparisons to 2012. The filing was signed April 16, 2015; its exhibits also refer inconsistently to a quarter ended December 31, 2012.
Financial results and position
| Metric | Three months ended March 31, 2013 | Six months ended March 31, 2013 |
|---|---|---|
| Revenue | $761 | $7,787 |
| Operating expenses | $21,213 | $165,673 |
| Operating loss | $(20,452) | $(157,886) |
| Interest expense | $(16,187) | $(32,556) |
| Net loss | $(104,276) | $(190,442) |
| Net loss available to common shareholders | $(107,624) | $(197,138) |
| Basic and diluted loss per share | $(0.00) | $(0.00) |
Gross profit and margins are not separately presented. The statements report a $67,637 income-tax expense for the quarter, although MD&A says no income-tax provision was made; the filing does not reconcile this discrepancy.
- Balance sheet at March 31, 2013: Total assets were $251,342, including cash of $788. Current liabilities were $2,092,258, against current assets of $13,276. Shareholders’ deficit was $1,840,916.
- Obligations: The balance sheet lists $1,138,501 of current related-party notes payable, a $604,330 judgment payable, $173,308 of interest payable, and $164,959 of accounts payable and accrued expenses. The filing separately discloses defaults on three promissory notes, with amounts owed totaling $306,812.
- Cash flow for six months: Operating activities used $37,598; investing activities were nil; financing activities provided $25,000. Cash declined by $12,598, from $13,386 to $788. No interest or income taxes were paid.
Changes versus prior period and management commentary
- Quarterly revenue fell from $3,665 to $761, while six-month revenue increased from $5,714 to $7,787. Revenue in both periods came from one customer.
- Operating expenses declined year over year by approximately $213,000 for the quarter and $630,000 for six months, which management attributed to reduced staffing and lower professional fees.
- Quarterly net loss improved from $342,840 to $104,276. Six-month net loss improved from $619,980 to $190,442; the prior-year six-month results included $228,802 of debt-forgiveness income, while the current period had none. Interest expense declined year over year for the six-month period.
- Management cited substantial working-capital deficits and negative cash flows and stated the company filed for Chapter 7 bankruptcy on May 15, 2013. The filing says it later emerged on September 19, 2014, with liabilities settled and the corporate shell as its only asset. It also reports liabilities exceeding assets by approximately $1.9 million in the bankruptcy discussion.
- The company disclosed that disclosure controls were ineffective because its small finance staff lacked segregation of duties. It reported no material changes to internal controls during the six months.
Outlook, risks, and unusual items
- No operating guidance is provided. Management’s stated risks included the ability to commercialize its technology, generate revenue and reach profitability, raise capital, maintain intellectual property, and develop sales, supply, and manufacturing capabilities.
- The statements were prepared on a going-concern basis despite losses, working-capital deficits, and negative cash flows; the filing notes that the company subsequently entered Chapter 7 bankruptcy.
- A $604,330 judgment arose from litigation with a noteholder; accrued interest on the judgment was reported separately. The filing also describes employment and lease commitments.
- The company’s prior business involved UV-curable coatings, but the filing says that business description no longer applied following bankruptcy and emergence as a corporate shell.
Important facts for investors to verify
- Confirm the registrant and filing identity: the supplied document names Ecology Coatings, Inc., not ABVC Biopharma, Inc.
- Verify the correct reporting period and filing date; the cover, exhibits, and period descriptions contain inconsistencies, and the report was signed in 2015 for 2013 financial statements.
- Reconcile the reported quarterly tax expense with MD&A’s statement that no provision was made.
- Review the bankruptcy disposition, settlement of liabilities, and the company’s post-bankruptcy assets and operations.
- Assess the status and terms of the defaulted notes, judgment, and other reported liabilities, as well as the disclosed ineffective controls.